Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
2(40%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_1
2
40%
Ph phase_2
2
40%
Ph not_applicable
1
20%

Phase Distribution

2

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
2(40.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(3)

Detailed Status

Completed3
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (40.0%)
Phase 22 (40.0%)
N/A1 (20.0%)

Trials by Status

recruiting240%
completed360%

Recent Activity

2 active trials
Showing 5 of 5
recruitingphase_1

A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants

NCT06889701
recruitingnot_applicable

ConsideRAte Study - Splenic Stimulation for RA

NCT05003310
completedphase_2

Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)

NCT01979016
completedphase_1

Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis

NCT01385657
completedphase_2

Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer

NCT01426880

Clinical Trials (5)

Showing 5 of 5 trials
NCT06889701Phase 1

A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants

Recruiting
NCT05003310Not Applicable

ConsideRAte Study - Splenic Stimulation for RA

Recruiting
NCT01979016Phase 2

Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)

Completed
NCT01385657Phase 1

Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis

Completed
NCT01426880Phase 2

Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5